Baricitinib + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Sep 9, 2019 → Apr 1, 2022
NCT ID
NCT03843125About Baricitinib + Placebo
Baricitinib + Placebo is a phase 3 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is terminated. This product is registered under clinical trial identifier NCT03843125. Target conditions include Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07222332 | Phase 3 | Recruiting |
| NCT07222137 | Phase 3 | Recruiting |
| NCT05237388 | Phase 2 | Recruiting |
| NCT05723198 | Phase 3 | Recruiting |
| NCT04421027 | Phase 3 | Completed |
| NCT03843125 | Phase 3 | Terminated |
| NCT03899259 | Phase 3 | Completed |
| NCT03742973 | Phase 2 | Terminated |
| NCT03773978 | Phase 3 | Completed |
| NCT03570749 | Phase 2/3 | Completed |
| NCT03616964 | Phase 3 | Completed |
| NCT03616912 | Phase 3 | Terminated |
| NCT03334435 | Phase 3 | Completed |
| NCT03435081 | Phase 3 | Completed |
| NCT03334422 | Phase 3 | Completed |
| NCT03334396 | Phase 3 | Completed |
| NCT02758613 | Phase 1 | Completed |
| NCT02708095 | Phase 2 | Completed |
| NCT02265705 | Phase 3 | Completed |
| NCT01885078 | Phase 3 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus